GTHX - Rasio rega marang prakiraan pendapatan G1 Therapeutics Inc.

G1 Therapeutics (GTHX) - logo korporat

G1 Therapeutics, Inc. (GTHX) management is effectively monetizing a niche drug that ensures a stable cash flow. The GURU.Markets platform features a chart of the company's expected P/S, where 6.40 records a new level. The business relies on innovative bone marrow protection during chemotherapy, while outsourcing drug production to US CMOs to guarantee the reliability of all supplies.

G1 Pharma - Prakiraan rega marang pendapatan GTHX (periode 04.07.2022 - 28.09.2024)

Rincian metrik komprehensif lan analitis G1 Pharma (GTHX)

- rega pasar lan target rega analis:
Analisis umum perusahaan:G1 Therapeutics GTHX
Produk sing diprodhuksi G1 Therapeutics Inc.

Conservative capital demands transparency in the valuation of future flows from the biotech sector, where overstating the multiple leads to a correction upon a guidance miss. This projected price-to-sales ratio reflects the discounted value of future revenues for G1 Therapeutics, Inc. (GTHX), accounting for a high WACC and the costs of environmental modernization of plants, allowing the investor to assess the fair discount or the asset's overvaluation.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Incyte Corp. INCY|HUTCHMED Ltd (HCM) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|NUVB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Day One|MNPR: Multiplikator Forward P/S|Prakiraan rega marang pendapatan Inhibrx Biosciences Inc INBX|Multiplikator forward rega marang pendapatan IMAB|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Fennec Pharmaceuticals FENC|Multiplikator forward rega marang pendapatan HRTX (Heron)|NVCT (Nuvectis Pharma) - Rega forward marang dodolan|Coherus Biosciences - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake CRBP (Corbus Pharmaceuticals Holdings)|Cardiff Oncology - Multiplikator Forward P/S|Rega forward marang dodolan BYSI (BeyondSpring Pharma)|BCAB: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep lixte.com (LIXT)|Rasio rega marang prakiraan pendapatan citiuspharma.com|CLRB: Rega forward marang dodolan|Multiplikator Forward P/S BLRX|Multiplikator Forward P/S Can-Fite (CANF)|Rasio rega marang prakiraan pendapatan Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Rega mangsa ngarep marang pendapatan|SLXN: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep NuCana|CMRX: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Cyclacel Pharmaceuticals|Rasio rega marang prakiraan pendapatan Kronos Bio, Inc.|kintara.com (KTRA) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S ONCT|PRTG (Portage) - Rega forward marang dodolan